Literature DB >> 23355343

Time delay of baroreflex control and oscillatory pattern of sympathetic activity in patients with metabolic syndrome and obstructive sleep apnea.

Edgar Toschi-Dias1, Ivani C Trombetta, Valdo J Dias da Silva, Cristiane Maki-Nunes, Felipe X Cepeda, Maria-Janieire N N Alves, Luciano F Drager, Geraldo Lorenzi-Filho, Carlos E Negrao, Maria Urbana P B Rondon.   

Abstract

The incidence and strength of muscle sympathetic nerve activity (MSNA) depend on the magnitude (gain) and latency (time delay) of the arterial baroreflex control (ABR). However, the impact of metabolic syndrome (MetS) and obstructive sleep apnea (OSA) on oscillatory pattern of MSNA and time delay of the ABR of sympathetic activity is unknown. We tested the hypothesis that MetS and OSA would impair the oscillatory pattern of MSNA and the time delay of the ABR of sympathetic activity. Forty-three patients with MetS were allocated into two groups according to the presence of OSA (MetS + OSA, n = 21; and MetS - OSA, n = 22). Twelve aged-paired healthy controls (C) were also studied. OSA (apnea-hypopnea index > 15 events/h) was diagnosed by polysomnography. We recorded MSNA (microneurography), blood pressure (beat-to-beat basis), and heart rate (EKG). Oscillatory pattern of MSNA was evaluated by autoregressive spectral analysis and the ABR of MSNA (ABRMSNA, sensitivity and time delay) by bivariate autoregressive analysis. Patients with MetS + OSA had decreased oscillatory pattern of MSNA compared with MetS - OSA (P < 0.01) and C (P < 0.001). The sensitivity of the ABRMSNA was lower and the time delay was greater in MetS + OSA compared with MetS - OSA (P < 0.001 and P < 0.01, respectively) and C (P < 0.001 and P < 0.001, respectively). Patients with MetS - OSA showed decreased oscillatory pattern of MSNA compared with C (P < 0.01). The sensitivity of the ABRMSNA was lower in MetS - OSA than in C group (P < 0.001). In conclusion, MetS decreases the oscillatory pattern of MSNA and the magnitude of the ABRMSNA. OSA exacerbates these autonomic dysfunctions and further increases the time delay of the baroreflex response of MSNA.

Entities:  

Mesh:

Year:  2013        PMID: 23355343     DOI: 10.1152/ajpheart.00848.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  15 in total

1.  Obstructive Sleep Apnea Impairs Postexercise Sympathovagal Balance in Patients with Metabolic Syndrome.

Authors:  Felipe X Cepeda; Edgar Toschi-Dias; Cristiane Maki-Nunes; Maria Urbana P B Rondon; Maria Janieire N N Alves; Ana Maria F W Braga; Daniel G Martinez; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrao; Ivani C Trombetta
Journal:  Sleep       Date:  2015-07-01       Impact factor: 5.849

2.  Blood Pressure Increases in OSA due to Maintained Neurovascular Sympathetic Transduction: Impact of CPAP.

Authors:  Renaud Tamisier; Can Ozan Tan; Jean-Louis Pepin; Patrick Levy; J Andrew Taylor
Journal:  Sleep       Date:  2015-12-01       Impact factor: 5.849

3.  Diet associated with exercise improves baroreflex control of sympathetic nerve activity in metabolic syndrome and sleep apnea patients.

Authors:  Edgar Toschi-Dias; Ivani C Trombetta; Valdo J D Silva; Cristiane Maki-Nunes; Felipe X Cepeda; Maria Janieire N N Alves; Glauce L Carvalho; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrão; Maria Urbana P B Rondon
Journal:  Sleep Breath       Date:  2018-06-11       Impact factor: 2.816

4.  Exercise training prevents the deterioration in the arterial baroreflex control of sympathetic nerve activity in chronic heart failure patients.

Authors:  Raphaela V Groehs; Edgar Toschi-Dias; Ligia M Antunes-Correa; Patrícia F Trevizan; Maria Urbana P B Rondon; Patrícia Oliveira; Maria J N N Alves; Dirceu R Almeida; Holly R Middlekauff; Carlos E Negrão
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

5.  Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.

Authors:  Isabelle Magalhães Guedes Freitas; Leonardo Barbosa de Almeida; Natália Portela Pereira; Pedro Augusto de Carvalho Mira; Rogério Baumgratz de Paula; Daniel Godoy Martinez; Edgar Toschi-Dias; Mateus Camaroti Laterza
Journal:  Clin Auton Res       Date:  2017-04-06       Impact factor: 4.435

6.  [Correlation of obstructive sleep apnea with components of metabolic syndrome and implications for long-term adverse cardiovascular risk in elderly patients].

Authors:  X Su; J Han; Y Gao; Z He; Z Zhao; J Lin; J Guo; K Chen; Y Gao; L Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

Review 7.  Dysfunctional brain-bone marrow communication: a paradigm shift in the pathophysiology of hypertension.

Authors:  Monica M Santisteban; Jasenka Zubcevic; David M Baekey; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

8.  Increased Muscle Sympathetic Nerve Activity and Impaired Executive Performance Capacity in Obstructive Sleep Apnea.

Authors:  Thiago T Goya; Rosyvaldo F Silva; Renan S Guerra; Marta F Lima; Eline R F Barbosa; Paulo Jannuzzi Cunha; Denise M L Lobo; Carlos A Buchpiguel; Geraldo Busatto-Filho; Carlos E Negrão; Geraldo Lorenzi-Filho; Linda M Ueno-Pardi
Journal:  Sleep       Date:  2016-01-01       Impact factor: 5.849

9.  Influences of obstructive sleep apnea on blood pressure variability might not be limited only nocturnally in middle-aged hypertensive males.

Authors:  Liang Shao; Mulalibieke Heizhati; Xiaoguang Yao; Yingchun Wang; Suofeiya Abulikemu; Delian Zhang; Ling Zhou; Jing Hong; Nanfang Li
Journal:  Sleep Breath       Date:  2017-11-17       Impact factor: 2.816

10.  The role of increased glucose on neurovascular dysfunction in patients with the metabolic syndrome.

Authors:  Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Akothirene C B Dutra-Marques; Jefferson C Carvalho; Valéria Costa-Hong; Maria Janieire N N Alves; Maria Urbana P B Rondon; Luiz A Bortolotto; Ivani C Trombetta
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-04       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.